1-(4-azido-2-fluoro-phenyl)-piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-(4-azido-2-fluoro-phenyl)-piperazine
• 英文别名: 1-(4-Azido-2-fluorophenyl)piperazine；1-(4-azido-2-fluorophenyl)piperazine
• 化学式: C₁₀H₁₂FN₅
• 分子量: 221.237
• InChiKey: ZHRAJLACCOSTKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  29.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(4-azido-2-fluoro-phenyl)-piperazine 、 溴乙酰溴 在 4-二甲氨基吡啶 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 13.0h， 以23%的产率得到1-[4-(4-azido-2-fluoro-phenyl)-piperazin-1-yl]-2-bromo-ethanone
  参考文献：
  名称：

  [EN] TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  [FR] NOUVEAUX COMPOSES DE TRIAZOLE EN TANT QU'AGENTS ANTIBACTERIENS ET COMPOSITIONS PHARMACEUTIQUES EN CONTENANT

  摘要：

  公开号：

  WO2005082892A3

文献信息

• Discovery of 8-(6-Methoxypyridin-3-yl)-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,5-dihydro-<i>4H</i>-[1,2,3]triazolo[4,5-<i>c</i>]quinolin-4-one (CQ211) as a Highly Potent and Selective RIOK2 Inhibitor
  作者：Yifan Ouyang、Hongfei Si、Chengjun Zhu、Liang Zhong、Haowen Ma、Zongyang Li、Huilan Xiong、Tongzheng Liu、Zhong Liu、Zhang Zhang、Zhi-Min Zhang、Qian Cai

  DOI：10.1021/acs.jmedchem.2c00271

  日期：2022.6.9

  in both enzymatic and cellular studies. It also exhibits potent proliferation inhibition activity against multiple cancer cell lines and demonstrates promising in vivo efficacy in mouse xenograft models. The crystal structure of RIOK2-CQ211 sheds light on the molecular mechanism of inhibition and informs the subsequent optimization. The study provides a cell-active chemical probe for verifying RIOK2
• [EN] NOVEL MONOSULFONYLATED AND CARBONYLATED CHIRAL COMPOUNDS DERIVED FROM A DIAMINE OR AN AMINOALCOHOL AND CARRYING A PYRROLIDINYL GROUP, THE PREPARATION THEREOF, AND THE APPLICATIONS OF THE SAME IN ASYMMETRICAL CATALYSIS<br/>[FR] NOUVEAUX COMPOSES CHIRAUX DERIVES D'UNE DIAMINE OU D'UN AMINOALCOOL, MONOSULFONYLES ET CARBONYLES PORTEURS D'UN GROUPE PYRROLIDINYLE, LEUR PREPARATION ET LEURS APPLICATIONS EN CATALYSE ASYMETRIQUE
  申请人：RHODIA CHIMIE SA

  公开号：WO2005080299A1

  公开（公告）日：2005-09-01

  La présente invention a pour objet de nouveaux composés chiraux dérivés d'une diamine ou d'un aminoalcool, monosulfonylés et carbonylés, porteurs d'un groupe pyrrolidinyle, leur préparation et leurs applications en catalyse asymétrique. L'invention vise plus particulièrement l'utilisation desdits composés comme catalyseurs organiques utiles notamment, pour la réaction d'aldolisation ou de cétolisation asymétrique.
• [EN] NOVEL TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND THEIR PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES DE TRIAZOLE EN TANT QU'AGENTS ANTIBACTERIENS ET COMPOSITIONS PHARMACEUTIQUES EN CONTENANT
  申请人：REDDYS LAB LTD DR

  公开号：WO2005082892A2

  公开（公告）日：2005-09-09

  The present invention relates to novel triazole compounds of formula (I), where all symbols are as defined in the detailed description; their pharmaceutically acceptable salts their stereosiomers thereof, their prodrugs, their rotamers, their pharmaceutical compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds.
• [EN] PROCESS FOR PREPARING BENZODIAZEPINES<br/>[FR] PROCEDE DE PREPARATION DE BENZODIAZEPINES
  申请人：ARROW THERAPEUTICS LTD

  公开号：WO2005090319A1

  公开（公告）日：2005-09-29

  A process for producing a compound which is a benzodiazepine derivative of formula: (I) wherein: represents or R1 represents C1-6 alkyl, aryl or heteroaryl; each R3 is the same or different and represents halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, amino, mono(C1-6 alkyl)amino, di(C1-6 alkyl)amino, nitro, cyano, -CO2R/, -CONR/R//, -NH-CO-R/, -S(O)R/, -S(O)2R/, -NH-S(O)2R/, -S(O)NR/R// or -S(O)2NR/R//, wherein each R/ and R// is the same or different and represents hydrogen or C1-6 alkyl; n is from 0 to 3; X represents -NH-, -N(C1-C6 alkyl)-, -CO-, -CO-NR/-, -S(O)- or -S(O)2-, wherein R/ is hydrogen or a C1-C6 alkyl group; and R4 represents hydrogen; or -CO-R4' or -CO-NH-R4', wherein R4' is a C1-C6 alkyl, C1-C6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group, which group is substituted by a C1-C6 hydroxyalkyl, aryl, heteroaryl, carbocyclyl or heterocyclyl group or a -(C1-C4 alkyl)-X1-(C1-C4 alkyl)-X2-(C1-C4 alkyl) group, wherein X1 represents -O-, -S- or -NR/-, wherein R/ represents H or a C1-C4 alkyl group and X2 represents -CO-, -SO- or -SO2-; or R4' represents -A1-Y-A2, wherein: Al is an aryl, heteroaryl, carbocyclyl or heterocyclyl group; Y represents a direct bond or a C1-C4 alkylene, -SO2-, -CO-, -O-, -S or -NR/-, wherein R/ is a C1-C6 alkyl group; and A2 is an aryl, heteroaryl, carbocyclyl or heterocyclyl group; or R4 is a group selected from aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- and -ZR5, wherein: Z represents -CO-, -S(O)- or -S(O)2-; and R5 represents C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)-, heterocyclyl-(C1-6 alkyl)-, aryl-(C1-6 alkyl)-O-, heteroaryl-(C1-6 alkyl)-O-, carbocyclyl-(C1-6 alkyl)-O-, heterocyclyl-(C1-6 alkyl)-O- or -NR/R// wherein each R/ and R// is the same or different and represents hydrogen, C1-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(C1-6 alkyl)-, heteroaryl-(C1-6 alkyl)-, carbocyclyl-(C1-6 alkyl)- or heterocyclyl-(C1-6 alkyl)-; or a pharmaceutically acceptable salt thereof; which process comprises: (a) subjecting a racemic benzodiazepine derivative of formula: (IIa): wherein R1, R3, R4, n and X are as defined above, and R2 represents an amino protecting group, to crystallisation induced dynamic resolution to yield a benzodiazepine derivative of formula (II): wherein, R1, R2, R3, R4, n and X are as defined above; and (b) deprotecting the benzodiazepine derivative of formula (II) as defined above to yield a benzodiazepine derivative of formula (I) or a pharmaceutically acceptable form thereof as defined above.
• [EN] TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES DE TRIAZOLE EN TANT QU'AGENTS ANTIBACTERIENS ET COMPOSITIONS PHARMACEUTIQUES EN CONTENANT
  申请人：REDDYS LAB LTD DR

  公开号：WO2005082892A3

  公开（公告）日：2006-03-23